



7th Immune Effector Cell Therapies in Multiple Myeloma Workshop

Boston, MA • March 27-28, 2026

Friday, March 27

8:00 - 8:10

INTRODUCTION AND WELCOME

Nikhil Munshi, Hermann Einsele, Adam Cohen

8:10 - 8:50

PLENARY TALK

8:10 - 8:40

Title TBC

Katy Rezvani

8:40 - 8:50

Audience Q&A

8:50 - 10:10

SESSION 1: CLINICAL UPDATES ON CAR T CELLS

Chairs: Jesus San Miguel and Sonja Zweegman

8:50 - 9:00

Ide-cel and Cilta-cel: Latest Updates and Ongoing Trials

Peter Voorhees

9:00 - 9:10

Latest Real World Data for CAR T Cells

Doris Hansen

9:10 - 9:20

Update on Anito-cel and GC012F

Matthew Frigault

9:20 - 9:30

GPRC5D CAR T Cells: Latest Updates and Ongoing Trials

Susan Bal

9:30 - 9:40

Dual-targeted CAR T Cell Approaches

Sham Mailankody

9:40 - 10:10

Discussion

Session faculty +
Rakesh Popat

10:10 - 10:40

BREAK

10:40 - 12:00

SESSION 2: CLINICAL UPDATES ON BISPECIFIC ANTIBODIES

Chairs: Shaji Kumar and Noopur Raje

10:40 - 10:50

Teclistamab and Talquetamab for Relapsed MM:
Latest Updates and Ongoing Trials

Saad Usmani

10:50 - 11:00

Elranatamab and Linvoseltamab for Relapsed MM:
Latest Updates and Ongoing Trials

Paula Rodriguez-Otero

11:00 - 11:10

Real World Data for Bispecific Antibodies

Cyrille Touzeau

11:10 - 11:20

Bispecific Abs for First-line and Maintenance Therapy

Elena Zamagni

11:20 - 11:30

Etentamig and Cevostamab: Latest Updates
and Ongoing Trials

Joshua Richter

11:30 - 12:00

Discussion

Session faculty +
Suzanne Trudel

12:00 - 1:00

LUNCH

1:00 - 2:30

SESSION 3: NOVEL APPROACHES IN THE CLINIC

Chairs: Kenneth Anderson and Suzanne Lentzsch

1:00 - 1:10

Trispecific Antibodies for Myeloma

Hang Quach

1:10 - 1:20

Combining Bispecific Abs with CAR T Cells

Binod Dhakal

1:20 - 1:30

Fixed Duration Bispecific Antibody Therapy

Meera Mohan

1:30 - 1:40

Augmenting T Cell Therapies with Proteasome Inhibitors

Florian Bassermann

1:40 - 1:50

TriPRIL CAR T Cells

Marcela Maus

1:50 - 2:00

Bispecific with Anti-CD38 Antibody

P. Joy Ho

2:00 - 2:30

Discussion
Green

Session faculty + Damian

2:30 - 3:00

BREAK

3:00 - 4:20

SESSION 4: TOXICITIES OF T CELL ENGAGING THERAPIES

Chairs: Martin Kaiser and Philippe Moreau

3:00 - 3:10

Pre-treatment Parameters Predicting CAR T Cell Toxicities

Adam Sperling

3:10 - 3:20

Elevated ALC and CAR T Cell Toxicities

Yi Lin

3:20 - 3:30

Managing Immune Effector Cell-associated
HLH-like Syndrome

Krina Patel

3:30 - 3:40

Managing CAR-T-associated Delayed Neurotoxicity

Andrew Yee

3:40 - 3:50

CAR T-related Lymphomas:
Clinical and Mechanistic Insights

Samir Parekh

3:50 - 4:20

Discussion

Session faculty +
Surbhi Sidana

4:20 - 5:40

SESSION 5: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPIES

Chairs: Sagar Lonial and Salomon Manier

4:20 - 4:30

Sequencing BCMA-directed Therapies: How to Choose?

TBD

4:30 - 4:40

Optimizing Outpatient Bispecific Ab and CAR T Cell
Administration

Omar Nadeem

4:40 - 4:50

Managing Extramedullary Disease
with T cell-redirecting Therapies

Martin Kortüm

4:50 - 5:00

T Cell Therapies for CNS Myeloma

Mahmoud Gaballa

5:00 - 5:10

Impact of CHIP on Outcomes after CAR T Cell Therapy

Niccolo Bolli

5:10 - 5:40

Discussion

Session faculty +
Francesca Gay

5:40 - 5:45

CONCLUSION

Saturday, March 28

8:00 - 8:05

WELCOME

Nikhil Munshi, Hermann Einsele, Adam Cohen

8:05 - 9:25

SESSION 6: UNDERSTANDING RESPONSE AND RESISTANCE TO T CELL THERAPIES

Chairs: Adam Cohen and Irene Ghobrial

8:05 - 8:15

Genomic Drivers of Resistance to BCMA-targeted Therapies

Francesco Maura

8:15 - 8:25

Mechanisms of Antigen Escape following GPRC5D-targeted Therapies

Paola Neri

8:25 - 8:35

Immune Correlates of Response to BCMA CAR T Cells

Maximilian Merz

8:35 - 8:45

Microenvironmental Factors Impacting Response/resistance

Marc Raab

8:45 - 8:55

Impact of Soluble BCMA on CART and Bispecific Ab Therapies

Ciara Freeman

8:55 - 9:25

Discussion

Session faculty + Mehmet Samur

9:25 - 10:35

SESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 1

Chairs: David Avigan and Maria-Victoria Mateos

9:25 - 9:35

In Situ Visualization of Bispecific Abs and MM Microenvironment

Edwin Hawkins

9:35 - 9:45

Targeting S100A8/9 to Enhance T Cell Therapies

Oliver Van Oekelen

9:45 - 9:55

Overcoming T Cell Exhaustion

Niels van de Donk

9:55 - 10:05

Modulating the Microbiome to Enhance CAR T Cell Therapy

Mireia Uribe-Herranz

10:05 - 10:35

Discussion

Session faculty + Madhav Dhodapkar

10:35 - 11:05

BREAK

11:05 - 12:30

SESSION 8: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 2

Chairs: Nizar Bahlis and Kwee Yong

11:05 - 11:15

Novel T Cell Therapy Targets for Myeloma

Sophia Danhof

11:15 - 11:25

CAR T Cells Against CD70

Arun Wiita

11:25 - 11:35

Targeting Intra-cellular Targets

Jianzhu Chen

11:35 - 11:45

EZH1/2 inhibition to augment cellular therapy

Patrizia Porazzi

11:45 - 11:55

Engineering of First in Class CAR Bugs for Cancer Immunotherapy

Romee Rizwan

11:55 - 12:30

Discussion

Session faculty

12:30 - 1:30

LUNCH

1:30 - 2:30

SESSION 9: CHALLENGING CASES IN IMMUNE EFFECTOR CELL THERAPY

Chairs: Ajai Chari and Sundar Jagannath

1:30 - 1:50

Case 1

TBD

1:50 - 2:10

Case 2

TBD

2:10 - 2:30

Case 3

TBD

2:30 - 3:40

SESSION 10: IN VIVO APPROACHES

Chairs: Hermann Einsele and Nikhil Munshi

2:30 - 2:40

Science of In Vivo CAR T Cell Therpay

Haig Aghajanian

2:40 - 2:50

Bedside CAR T Cell Production

Michael Hudecek

2:50 - 3:00

In Vivo Bispecific Therapy

Eric Smith

3:00 - 3:10

Clinical Results of In Vivo CAR T Cell Therapy

Heng Mei

3:10 - 3:20

Clinical Results of In Vivo CAR T Cell Therapy Part II

Simon Harrison

3:20 - 3:40

Discussion

Session faculty

3:40 - 3:45

CONCLUSION AND WRAP-UP